Tvardi Therapeutics: TTI-109 advanced for UC after positive topline results; Q2 net loss was $6.5 millionQuartr·Aug 14 at 06:09 AMTVRD0.00%
Tvardi Therapeutics to host KOL webinar on TTI-109 potential in ulcerative colitisPUBT·Aug 12 at 07:08 AMTVRD0.00%
Tvardi Therapeutics plans 2027 mid-to-late stage ulcerative colitis trial for STAT3 inhibitor TTI-109PUBT·Jul 30 at 06:36 AMTVRD0.00%
Power On: SkyWater’s Quantum Leap and Nakamoto’s Bitcoin PivotGlobal Report·Jul 17 at 04:11 AMSKYT0.00%NAKA-2.64%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Jul 9 at 12:05 PMVRAX0.00%IONS+1.58%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Jul 8 at 04:05 PMAPVO-1.66%BRTX+3.19%
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·Jul 8 at 12:05 PMCUPR0.00%TVRD0.00%
Tvardi Therapeutics reports Phase 1 data for STAT3 inhibitor prodrug TTI-109 showing improved tolerabilityPUBT·Jul 7 at 06:01 AMTVRD0.00%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Jul 7 at 12:05 PMCRNX+0.04%AKTX+6.16%
